Why Paychex Stock Is Back in Focus After the Paycor Perks Launch

Paychex (PAYX) is drawing fresh attention after expanding its lifestyle benefits offering to Paycor clients with the launch of Paycor Perks, a voluntary benefits marketplace embedded directly into the Paycor HCM platform.

The move gives Paycor client employees access to financial wellness tools, supplemental insurance, entertainment discounts and other voluntary benefits at no cost to employers, and it broadens how Paychex participates in the wider human capital management ecosystem.

Alongside the Paycor Perks launch, Paychex has seen strong recent share price momentum, with a 30 day share price return of 10.97% and a 90 day share price return of 32.92%, even though the 1 year total shareholder return declined 5.01%.

If you are thinking about how this kind of product expansion compares with other growth stories, it can help to widen your search and review the 20 top founder-led companies

After the sharp recent run in Paychex stock and the broader push into lifestyle benefits through Paycor Perks, the real issue now is simple: Does the current valuation still leave enough upside for new buyers given the risks?

Most Popular Narrative: 15% Overvalued

Paychex last closed at $126.01, which is above the most widely followed fair value estimate of $109.57 that uses a 7.48% discount rate.

The analysts have a consensus price target of $109.57 for Paychex based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $150.0, and the most bearish reporting a price target of just $95.0.

Want to see what sits behind that spread in views on Paychex? The narrative leans on a detailed path for revenue, margins and the future earnings multiple.

Result: Fair Value of $109.57 (OVERVALUED)

However, Paychex still faces execution risk around integrating Paycor and potential pressure on margins if employee costs and client health plan choices move against current projections.

Another View On Paychex Valuation

There is a sharp contrast between analyst fair value estimates for Paychex and the Simply Wall St DCF model. While analysts see fair value at $109.57 and the current $126.01 share price as about 15% above that level, the SWS DCF model suggests fair value closer to $189.47, which implies the stock trades about 33.5% below that estimate. Which set of assumptions do you trust more?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Paychex for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the mix of optimism and concern around Paychex right now, it makes sense to review the data yourself and decide quickly where you stand. A good place to start is by weighing the 3 key rewards and 2 important warning signs.

Looking For More Investment Ideas Beyond Paychex?

If Paychex has sharpened your interest, do not stop with a single stock. Broadening your watchlist now can help you spot opportunities others overlook.

• Scan for potential value opportunities by reviewing the 49 high quality undervalued stocks that pair solid fundamentals with more modest pricing.
• Focus on stability and defense first by checking out the 74 resilient stocks with low risk scores that screen for resilient balance sheets and lower risk scores.
• Hunt for tomorrow's potential leaders early by reviewing the screener containing 18 high quality undiscovered gems that highlight quality businesses still off many investors' radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.